← Leaderboards
David Gius
University Of Texas Hlth Science Center
$12,824,808
Attributed
$12,824,808
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,824,808 · 7
By mechanism
R01$12,741,389 · 6
K08$83,419 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Science Center
Same institution · by research overlap
- Peter J Houghton$32,798,876
- Charles P France$39,306,016
- Nicolas Musi$26,908,346
- Sara Elyse Espinoza$5,415,964
- Manjeet Kumar Rao$4,238,035
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorCellsPhenotypeExhibitsMalignant NeoplasmsIn VivoMitochondriaLinkGenesProteinsSuperoxidesMetabolismReactive Oxygen SpeciesAcetylationLysineSignal TransductionLaboratoriesPreventNeoplastic CellPathway InteractionsMutantMetabolicEventTissue Culture
Grant awards (60)
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy$383,789
R01 · FY2025 · CA · contact PI
MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies$368,162
R01 · FY2025 · CA · contact PI
MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies$101,475
R01 · FY2025 · CA · contact PI
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy$364,601
R01 · FY2024 · CA · contact PI
MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies$349,755
R01 · FY2024 · CA · contact PI
MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies$144,601
R01 · FY2024 · CA · contact PI
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy$376,114
R01 · FY2023 · CA · contact PI
MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies$360,799
R01 · FY2023 · CA · contact PI
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy$68,128
R01 · FY2023 · CA · contact PI
MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies.$50,736
R01 · FY2023 · CA · contact PI
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy$376,114
R01 · FY2022 · CA · contact PI
MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies$360,799
R01 · FY2022 · CA · contact PI
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy$69,518
R01 · FY2022 · CA · contact PI
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotype$389,462
R01 · FY2021 · CA · contact PI
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy$382,941
R01 · FY2021 · CA · contact PI
MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies$366,683
R01 · FY2021 · CA · contact PI
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotype$390,240
R01 · FY2020 · CA · contact PI
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotype$72,799
R01 · FY2020 · CA · contact PI
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotype$378,533
R01 · FY2019 · CA · contact PI
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotype$396,910
R01 · FY2018 · CA · contact PI
Loss of Mitochondrial Sirt3, Decreased MnSOD Activity, and IR Induced Genomic Instability$361,344
R01 · FY2018 · CA · contact PI
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotype$396,495
R01 · FY2017 · CA · contact PI
Loss of Mitochondrial Sirt3, Decreased MnSOD Activity, and IR Induced Genomic Instability$362,822
R01 · FY2017 · CA · contact PI
ROS and HIFa as molecular targets for chemoprevention in Sirt3 -/- breast cancers$379,565
R01 · FY2016 · CA · contact PI
Loss of Mitochondrial Sirt3, Decreased MnSOD Activity, and IR Induced Genomic Instability$362,812
R01 · FY2016 · CA · contact PI
ROS and HIFa as molecular targets for chemoprevention in Sirt3 -/- breast cancers$379,565
R01 · FY2015 · CA · contact PI
Loss of Mitochondrial Sirt3, Decreased MnSOD Activity, and IR Induced Genomic Instability$362,734
R01 · FY2015 · CA · contact PI
SIRT3 is a Mitochondrial Tumor Suppressor in ER/PR Positive Mammary Tumors$314,718
R01 · FY2015 · CA · contact PI
Loss of mtSIRT3, Decreased MnSOD Activity, and IR Induced Genomic Instability$379,387
R01 · FY2014 · CA · contact PI
ROS and HIFa as molecular targets for chemoprevention in Sirt3 -/- breast cancers$368,178
R01 · FY2014 · CA · contact PI
SIRT3 is a Mitochondrial Tumor Suppressor in ER/PR Positive Mammary Tumors$306,676
R01 · FY2014 · CA · contact PI
Loss of mtSIRT3, Decreased MnSOD Activity, and IR Induced Genomic Instability$367,654
R01 · FY2013 · CA · contact PI
ROS and HIFa as molecular targets for chemoprevention in Sirt3 -/- breast cancers$356,791
R01 · FY2013 · CA · contact PI
SIRT3 is a Mitochondrial Tumor Suppressor in ER/PR Positive Mammary Tumors$297,722
R01 · FY2013 · CA · contact PI
Loss of mtSIRT3, Decreased MnSOD Activity, and IR Induced Genomic Instability$393,652
R01 · FY2012 · CA · contact PI
ROS and HIFa as molecular targets for chemoprevention in Sirt3 -/- breast cancers$379,565
R01 · FY2012 · CA · contact PI
SIRT3 is a Mitochondrial Tumor Suppressor in ER/PR Positive Mammary Tumors$318,828
R01 · FY2012 · CA · contact PI
Loss of mtSIRT3, Decreased MnSOD Activity, and IR Induced Genomic Instability$393,652
R01 · FY2011 · CA · contact PI
SIRT3 is a Mitochondrial Tumor Suppressor in ER/PR Positive Mammary Tumors$323,170
R01 · FY2011 · CA · contact PI
SIRT3 is a genomically expressed mitochondrial TSG$345,250
ZIA · FY2010 · CA · contact PI
Epigenetic Regulation of Gene Expression and Resistance in Tumor Cells$230,166
ZIA · FY2010 · CA · contact PI
Loss of mtSIRT3, Decreased MnSOD Activity, and IR Induced Genomic Instability$183,900
R01 · FY2010 · CA · contact PI
SIRT3 is a genomically expressed mitochondrial TSG$758,220
ZIA · FY2009 · CA · contact PI
Epigenetic Regulation of Gene Expression and Resistance in Tumor Cells$505,480
ZIA · FY2009 · CA · contact PI
Epigenetic Regulation of Gene Expression and Resistance in Tumor Cells$662,784
Z01 · FY2008 · CA · contact PI
HSP90 as a Molecular Target for Ionizing Radiation$441,856
Z01 · FY2008 · CA · contact PI
Epigenetic regulation of of Gene Expression and multi-modality resistance in tum$951,753
Z01 · FY2007 · CA · contact PI
HSP90 as a Molecular Target for Ionizing Radiation$634,503
Z01 · FY2007 · CA · contact PI
Epigenetic regulation of of Gene Expression and multi-mo$0
Z01 · FY2006 · BC · contact PI
HSP90 as a Molecular Target for Ionizing Radiation$0
Z01 · FY2006 · BC · contact PI
Epigenetic regulation of of Gene Expression and multi-mo$0
Z01 · FY2005 · BC
Sulfhydryl switches and free-radical scavenger involveme$0
Z01 · FY2005 · BC
HSP90 as a Molecular Target for Ionizing Radiation$0
Z01 · FY2005 · BC
Epigenetic regulation of Gene Expression and Multi-modal$0
Z01 · FY2003 · BC
Sulfhydryl switches and free-radical scavenger involveme$0
Z01 · FY2003 · BC
HSP90 as a Molecular Target for Ionizing Radiation$0
Z01 · FY2003 · BC
Redox Signaling &Cell Response to Ionizing Rceladiation$0
Z01 · FY2002 · BC
HSP as molecular targets for NSAIDs and Geldanamycin$0
Z01 · FY2002 · BC
Methylation Mechanism for Resistant Pheotype$0
Z01 · FY2002 · BC
GI RESTRICTION POINT &TCR ACTIVATION INDUCED APOPTOSIS$83,419
K08 · FY2000 · CA